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Clostridium difficile has emerged as an important cause of infection dur-
ing the past 10 to 15 years [1]. This organism causes an acute inflammation
of the colon, largely attributable to its release of toxins A and B into the
lumen. A syndrome of acute diarrheal disease follows, which is debilitating
and not infrequently lethal. Some authorities continue to use the phrase
‘‘C difficile–associated diarrhea’’ or ‘‘C difficile–associated disease’’ to de-
scribe this disease, but those terms are left over from the late 1970s when
the cause was still uncertain. A better descriptive term is ‘‘C difficile colitis’’
(CDC).
CDC was originally recognized exclusively as a nosocomial infection and,
subsequently, as a problem in extended care facilities [2]. Infection tends to
occur in bedridden patients, especially those who have underlying diseases
including malnutrition and other common debilitating conditions [3]. Early
reports suggested that nearly all patients received antibiotics before infec-
tion. Subsequently, it was shown that chemotherapy and the use of drugs
that inhibit gastric acidity strongly increase the risk of CDC [4]. In the
past few years, an increasing number of community-acquired cases have
been reported [5,6]; many of the patients who acquire this infection in the
community have not received antibiotics in the preceding 90 days [6,7].
In the epidemiologic setting of a hospitalized patient who has received
prior antimicrobial therapy or chemotherapy, the clinical syndrome of
CDC is usually easy to recognize. Abdominal discomfort and diarrhea,
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velop over a period of a few days. Fever is present in about half of patients
during the first few days of symptoms but, interestingly, may abate by the
time the diagnosis is considered, a stool sample is submitted, and results
of C difficile toxin are positive. About 40% of hospitalized patients have leu-
kocytosis (white blood cell O12,500/mm3); in the authors’ medical center,
25% of all patients who have peripheral white blood cell counts greater
than 30,000/mm3 have CDC [8]. Because this infection occurs in patients
who already have severe underlying diseases complicated by infection and
antibiotic treatment, or malignancy and chemotherapy [3], the diarrhea itself
contributes to further debilitation. As a result, CDC is associated with sub-
stantial mortality, nearly 20% in the first month after diagnosis and 27% in
3 months after diagnosis [9].
As with nearly every disease, the best approach is preventive. This article
emphasizes treatment of CDC, considers diagnostic techniques, and de-
scribes means for preventing the spread of this infection in the intensive
care setting.Treatment
Stopping the antibiotic
In early reports [10–12], 15% to 23% of patients with CDC had sponta-
neous resolution of symptoms within 48 to 72 hours of stopping the offend-
ing antibiotic and without specific antimicrobial therapy. This approach is
not recommended, except perhaps in outpatients who have very mild dis-
ease, certainly not in an intensive care setting. One cannot predict which
patients will clear the infection spontaneously, and it is often not feasible
to discontinue antibiotics. Furthermore, diarrhea contributes to contagion
[13] and, in the hospital setting, delaying initial therapy prolongs the period
of contagion. Finally, persons who develop CDC tend to be more debili-
tated and to have received more intensive antibiotic treatment than in the
past, suggesting that an even smaller proportion than originally reported
might respond to simple cessation of antibiotics.Specific therapy
Vancomycin
In vitro, C difficile is susceptible to vancomycin (minimum inhibitory
concentration [MIC]90, 1 mg/mL; range, 0.06–4 mg/mL) [14]. Oral vancomy-
cin was used to treat staphylococcal enterocolitis and clindamycin-associ-
ated diarrhea before the discovery that C difficile was responsible for the
disease [15–17]. Recognition of the role of Clostridium was followed by ad-
ditional studies using vancomycin for treatment [11,18–21]; doses ranging
from 125 to 500 mg four times daily were found to be equally effective
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patients with CDC [10–12,15,18–25] and is the only medication that has
a Food and Drug Administration indication for this infection. Reports
[26] of intermediate resistance to vancomycin (MIC, 4–16 mg/mL) have
not provided clinical correlations. Orally administered vancomycin is mini-
mally absorbed and has a mean stool concentration of up to 3100 mg/g [18],
suggesting that the resistance reported to date is not clinically important.Metronidazole
Reports of the MIC90 of metronidazole for C difficile ranges from 0.20 to
2.0 mg/mL with a median less than 1 mg/mL; [27–32]. A recent study [14]
showed that 100% of 110 isolates were inhibited by less than or equal to
0.5 mg/mL. There are scattered reports of resistance [26,28,30] with MICs
ranging from 8 to 64 mg/mL, but there is no clinical correlation. Our data
[9] and those from Hecht and colleagues [14] have shown that all isolates,
including those from clinical failures and the newly described epidemic
strain C difficile NAP-1 [33], remain fully susceptible.
In 1982, Cherry and colleagues [34] described 13 patients with CDC who
responded to 1.5 to 2 g of oral metronidazole daily for 7 to 10 days,
although two (15%) had recurrent disease. Soon thereafter, a randomized
trial [10] in 92 patients compared oral metronidazole, 250 mg four times
daily, with oral vancomycin, 500 mg four times daily, for 10 days. Rates
of response (88% for vancomycin and 90% for metronidazole) and recur-
rence within a 21-day follow-up period (12% for vancomycin and 5% for
metronidazole) were similar. A subsequent study confirmed a response
rate of 94% [35], and a Cochrane database analysis found no difference
between metronidazole and vancomycin in treating CDC [36].
The apparent equivalence of these two drugs, the remarkable price differ-
ential, and concern over the selection of vancomycin-resistant bacteria, espe-
cially within hospitals [37,38], led to a recommendation that metronidazole
be used as first-line therapy for CDC [39]. More recent articles, however,
have reported a much lower rate of success with metronidazole therapy
[9,40,41]. In these case series, about one quarter of patients failed to respond
to 2 weeks of metronidazole, and another one quarter had recurrence of
CDC within 2 months. At the time of this writing, an important double-
blind, prospective comparison has just confirmed that this drug is distinctly
inferior to oral vancomycin in moderately severe or severe cases [25], raising
further question about whether it has a continued place in treating this
disease [42], especially in critically ill patients (see later).
Pharmacokinetics provide a possible explanation for the high failure rate
with metronidazole. In healthy adults, after oral administration, metronida-
zole is completely absorbed from the gastrointestinal tract; fecal concentra-
tions are undetectable [43,44]. Levels of this drug in feces are, however,
significantly higher in CDC, with concentrations exceeding the MIC for
C difficile (mean concentration, 9.3 mg/g; range, 0.8–24 mg/g) [45]. In
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0.5–10.4 mg/g) and are undetectable in about 50% of patients during conva-
lescence (mean, 1.2 mg/g; range, 0–10.2 mg/g). The presence of metronidazole
in diarrheal stool specimens may reflect increased gastrointestinal transit
time leading to incomplete absorption or seepage of plasma containing
the drug across the inflamed colonic mucosa [45]; the authors favor the latter
explanation. The main point is, that as CDC responds to metronidazole
therapy, the drug concentration in the feces rapidly falls, and increasing
the dose or prolonging therapy is not likely to prevent relapses in patients
who have responded to therapy.
Because metronidazole is fully absorbed in the small intestine and yet
appears in feces during diarrhea, one might hypothesize that parenteral met-
ronidazole might also be useful in treating CDC. In three patients who re-
ceived intravenous metronidazole [45], fecal concentrations ranged from
6.3 to 24 mg/g of stool during acute illness but were significantly lower in
formed stool. A retrospective review of 10 patients with CDC initially
treated with intravenous metronidazole [46] revealed clinical improvement
in nine, an observation that has been supported by substantial personal
experience (unpublished data). Treatment with intravenous metronidazole
has an important place in treating critical care or postoperative patients.Nitazoxanide
Nitazoxanide is licensed to treat protozoan and helminthic infections [47]
and is probably the only drug that effectively treats cryptosporidiosis in
AIDS patients. This drug blocks anaerobic metabolic pathways and has
been shown to be effective against C difficile in vitro (MIC90, 0.06; range,
0.03–0.5 mg/mL) [14]. Approximately two thirds of the oral dose is excreted
in feces as tizoxanide, an active metabolite that has similar antibacterial
activity [14]. A prospective, double-blind control trial showed that oral nita-
zoxanide 500 mg twice daily for 10 days is at least as effective as metronida-
zole in treating CDC [3], and a case series showed the efficacy of this drug in
patients who failed metronidazole therapy [48]. This drug is relatively free of
complications, and bacteria resistance has not been observed.Rifaximin
Rifaximin is only minimally absorbed in the gastrointestinal tract after
oral administration. This drug is effective in vitro against gram-negative
and gram-positive flora, including anaerobic bacteria and C difficile
[14,49] and has been shown to provide effective treatment for traveler’s
diarrhea [50]. The MIC90 for C difficile is 0.008 mg/mL (range, !0.002–
0.05 mg/mL) [14]. Reports to date in treating CDC are limited. In an open
trial, 10 patients were treated with rifaximin, and nine were cured [51]. Eight
patients who had multiple recurrences of CDC were treated with a course of
vancomycin followed by 2 weeks of rifaximin; six were cured and a seventh
was cured by a second course of the same treatment [52]. Resistance to
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therapy, even though prior in vitro studies suggested that this was not likely
to occur [31]. A double-blind prospective trial comparing rifaximin with
vancomycin is nearing completion at the time of this writing.OPT-80
OPT-80 is also a nonabsorbed antimicrobial that is highly effective
against C difficile in vitro (MIC90, 0.008; range, 0.001–0.06 mg/mL) with
little effect against other gram-positive anaerobes and none against gram-
negative ones [53]. Based on these characteristics, this might seem to be
the best of the agents currently in development. A trial comparing OPT-80
with vancomycin is currently in progress.Treatments based on blocking toxin activityIn a critical care setting, an ideal therapy, either by itself or as an adjunct
to antimicrobial therapy, might be one that blocks toxin activity, because it
could lead to the most immediate reversal of disease. Several compounds
that exhibit this property have been studied, but there are no convincing
data to date that any has a place in the treatment of CDC.Agents that bind toxin
Colestipol and cholestyramine, anion exchange resins, bind the toxin pro-
duced by C difficile in vitro, but they seem to lack clinical efficacy [54–56],
and their potential is further compromised by the possibility that they
also bind orally administered drugs that are used to treat CDC, such as van-
comycin [57]. Tolevamer is a polyanionic compound that binds C difficile
toxins in the colon without affecting intestinal absorption of most drugs.
In a large randomized, double-blind trial comparing this drug with
vancomycin, however, it seemed to be inferior (unpublished information,
but available on a Genzyme Web site that deals with this compound). A
more relevant scientific question, namely whether tolevamer in addition to
vancomycin was associated with a better outcome than vancomycin alone,
especially in very ill subjects was not addressed by the study.Antibody to toxin
Anti–C difficile bovine immunoglobulin neutralizes the effects of toxin B
in a cell cytotoxicity assay and has been used to treat and prevent CDC in
rodents [58,59]. Monoclonal antibody to toxin A or to toxin B has shown
promising results in experimental animals [60]; phase II studies in humans
are currently in progress. Again, such agents should probably used together
with an effective antimicrobial that eradicates the C difficile or, at least, re-
turns it to its minor place in the colonic flora. The current study uses the
monoclonal antibody alone, and it is feared that, even if effective control
is achieved, the rate of relapse will be unacceptably high.
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kg) has been administered to patients with CDC [61–63]; in two studies that
included seven patients with refractory CDC, five seemed to be cured by this
treatment [62,63]. Somewhat surprisingly, Salcedo and colleagues [62] found
anti–C difficile toxin activity in all samples of pooled intravenous immuno-
globulin. A recent retrospective study at one medical center showed no ben-
efit from intravenous immunoglobulin [64]. Intravenous methylprednisolone
has also been used to treat CDC in a single pediatric case [65].
Vancomycin enemas and colonic infusions of normal feces have also been
recommended in refractory cases [66] based on a remarkably few case re-
ports [67–69]. Nevertheless, in critically ill subjects with CDC, especially if
bowel motility is compromised, intracolonic vancomycin is recommended.
One case series has described apparent success with nasogastric administra-
tion of feces from a healthy donor [70].Summary of treatment recommendationsTreatment of critically ill patients with metronidazole, a drug that only
arrests disease in 20% to 25% of patients and then has a high relapse rate,
is probably no longer appropriate. Vancomycin is proved to be effective,
and should probably be used under the ethical concept that the interests of
an individual patient must be weighed more heavily than a theoretic concern
for the general good. Nitazoxanide, rifaximin, or OPT-80 may become
acceptable alternatives if approved for such use, and might be preferred
because of the desire to avoid vancomycin in the hospital environment.Making the diagnosis
Because of the importance of prompt therapy in preventing the spread of
infection, clinicians need to be aware of how diagnoses are made, how
promptly, and how reliably [71]. In the early days of testing for C difficile
toxin, the cytotoxicity assay, which evaluated the presence of toxin based
on the effects of a filtered fecal sample on tissue-cultured cells, became the
gold standard. This test was regarded as being close to 100% sensitive
and 100% specific. By comparison, early ELISAs were much less sensitive;
three fresh specimens were required to achieve a sensitivity of 75%–85%.
These ELISAs have been improved. It was found that, among those several
that are commercially available in the United States, the sensitivity on a sin-
gle fecal sample is around 95%, and the specificity is greater than 95% [71].
Furthermore, recently developed rapid tests, based on adapting ELISA to
a card, are similarly reliable.
Laboratories that test many samples each day should probably continue
to use ELISA. For laboratories that have no more than one to two assays,
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can be done at any time (end of the day, off shift, and so forth) and by a less
extensively trained technologist.Surgical management
In the absence of appropriate treatment and, in some patients, even de-
spite optimal medical treatment, CDC may progress to severe sepsis, perito-
nitis, toxic colonic dilatation, or bowel perforation; mortality may exceed
50% [72,73]. It seems that the number of patients who have life-threatening
disease is now increasing [74–76]. Careful monitoring of these patients is
vital, because they may require early surgical intervention [77,78]. Total co-
lectomy has the lowest mortality in the treatment of fulminant CDC
compared with more limited colonic resection [79,80]; in a case series of
14 patients who underwent surgical management of fulminant colitis, the
30-day mortality was 10% for 10 patients treated with a total colectomy ver-
sus 100% in the four treated with a hemicolectomy. Early surgical consulta-
tion is recommended for the critically ill patient with CDC.Practical hints for managing Clostridium difficile colitis in intensive care
settings
Clostridium difficile is a hardy organism in its vegetative state and even
hardier once it sporulates; this organism can be exceedingly difficult to erad-
icate once it is in the environment. As a general matter, diarrhea poses the
threat of contagion; it is difficult to prevent soiling one’s own clothing, not
to mention hands, wrists, arms, and stethoscopes while examining or treat-
ing patients. Prevention of development and spread of this infection are
extremely important and are a vital concern for every health care provider
in the intensive care setting.
Minimizing unnecessary use of antibiotics is probably the highest prior-
ity, closely followed by reducing the use of proton pump inhibitors. Every
physician must weigh risks against benefits when prescribing these agents,
and one of the major risks, proved with absolute certainty in the literature
during the past two decades, is CDC. The possibility of this infection needs
to be considered at the first signs of abdominal discomfort or tenderness, un-
explained leukocytosis, or diarrhea.
When diarrhea develops, isolation measures should immediately be insti-
tuted (Box 1). A fecal specimen should be submitted promptly for testing.
The authors have found that nurses may need to be reminded to obtain stool
samples; it is helpful to teach the nursing staff the importance of early detec-
tion, isolation, and treatment. Except in special situations, looking for ova
and parasites or culturing for Shigella and Salmonella is a waste of re-
sources. Metronidazole may be ordered empirically at the time the diarrhea
Box 1. Practical hints for preventing spread of C difficile
in the ICU setting
1. Reduce use of antibiotics to only what is necessary
2. Reduce use of proton pump inhibitors similarly
3. Consider C difficile infection at first signs of abdominal
discomfort, unexplained increase in white blood cell count, or
diarrhea
4. Promptly isolate patient and submit fecal specimen
for testing
5. Insist that laboratory assays for C difficile toxin daily
6. Treat with metronidazole before results available
7. Treat with oral vancomycin if diagnosis proved
8. Repeat fecal assay if negative, continue metronidazole
9. Stop treatment if second test is negative
10. Continue isolation for CDC for at least a week into Rx
and longer if diarrhea persists
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negative, continued metronidazole until a second specimen can be assayed
is reasonable; if results are negative again and the patient has not responded,
metronidazole may be discontinued. Several years ago, it was noted that
some patients who fit the clinical picture of CDC with negative testing
may respond to this drug [81]; that work was done at a time that the sensi-
tivity of ELISA was not yet as good as it is now. Consistent with the data on
the relative efficacy of vancomycin versus metronidazole, the authors believe
that as soon as CDC is documented in a patient in the ICU, treatment with
vancomycin should begin. This approach meets all guidelines because it
avoids empiric use of vancomycin, yet promptly treats critically ill patients
with the most effective agent.
Finally, if there is an outbreak of CDC in an ICU (the United States Cen-
ters for Disease Control and Prevention tends to define an outbreak as R2
cases within a short period of time), physicians need to involve themselves in
the nitty-gritty of housekeeping procedures to be sure that terminal cleaning
(cleaning beds and the environment after discharge of patients) is being done
properly, including wiping down of all surface areas with bleach.Strategies to treat recurrent Clostridium difficile colitis
Various strategies have been proposed to treat recurrent CDC. If a patient
fails after being treated with vancomycin, longer courses of treatment may
be given, although this approach is not expected to be effective against
organisms that have sporulated. Vancomycin has been given in a pulsed
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days or in a decreasing dose allows the C difficile spores to germinate and be
susceptible to being killed by the antibiotic [82]. The reader should note that
this same approach was followed with penicillin for bacterial endocarditis in
the 1950s (Louis Weinstein, personal communication, 1967), but it was
abandoned by the mid-1960s. A combination of vancomycin and rifampin
has also been reported as effective treatment in a few cases [83]. The authors’
experience has been that this is a vexing problem with no satisfactory reso-
lution at present. It should be noted that the meaning of repeated detection
of C difficile toxin in the feces of patients who have been treated for CDC is
uncertain. In their recent study, Zar and colleagues [25] included such detec-
tion at 10 days as a treatment failure, but reanalysis of their data suggested
that there were very few patients who had toxin but were otherwise appar-
ently cured of their infection [84].Summary
CDC is a debilitating infection with a remarkably high associated mortal-
ity. Infection is contagious and spreads especially rapidly in an intensive
care setting because patients who are there have all the associated risk fac-
tors, including major underlying illnesses, prior antibiotic therapy, and use
of agents that suppress gastric acidity. Prevention of disease is the responsi-
bility of every health care provider in the critical care setting. Reduction of
nonindicated use antibiotics and proton pump inhibitors and meticulous at-
tention to infection control measures are central to this effort. Early recog-
nition, implementation of isolation precautions, and testing of feces for
C difficile toxin should be a priority, and currently available tests are highly
reliable. Failures with metronidazole therapy are common and, once a diag-
nosis of CDC is established, prompt treatment with a more effective drug
(at present vancomycin, but perhaps eventually nitazoxanide or one of the
newer ones in development) seems appropriate. Diagnoses should be
made rapidly, metronidazole instituted promptly while awaiting diagnosis,
and vancomycin given as soon as CDC is proved to be present.References
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